Cipla: Domestic market blues... - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Cipla: Domestic market blues...

Apr 28, 2003

Domestic pharma major, Cipla Ltd, has posted disappointing March numbers. The company has reported a marginal 2% dip in income from operations, but net profits shrunk by over 24% during the quarter. The company's operating margins nearly halved to just over 12% in 4QFY03.

(Rs m) 4QFY02 4QFY03 Change FY02 FY03 Change
Net Sales 3,943 3,882 -1.6% 14,005 15,724 12.3%
Other Income 21 111 440.0% 284 258 -9.0%
Expenditure 3,055 3,411 11.7% 10,961 12,561 14.6%
Operating Profit (EBDIT) 888 471 -47.0% 3,044 3,164 3.9%
Operating Profit Margin (%) 22.5% 12.1%   21.7% 20.1%  
Interest 5 9 76.0% 21 16 -22.4%
Depreciation 72 67 -6.7% 213 283 33.1%
Profit before Tax 832 506 -39.2% 3,094 3,122 0.9%
Tax 215 38 -82.1% 743 648 -12.8%
Profit after Tax/(Loss) 617 467 -24.3% 2,351 2,475 5.3%
Net profit margin (%) 15.7% 12.0%   16.8% 15.7%  
No. of Shares 60.0 60.0   60.0 60.0  
Diluted Earnings per share* 41.2 31.2   39.2 41.3  
P/E Ratio         15.4  
*(annualised)            

The company's domestic sales fell by 10% during the quarter (to about Rs 2 bn). The management seems to have attributed this to the slower domestic industry growth (about 2%-3%) during the quarter and also to the VAT worries owing to which stockists put off purchases until further clarity emerged on the issue. However, the dip in domestic sales was compensated by a 9% growth in export sales (to over Rs 1.9 bn). The export sales growth is very encouraging. The operating margin plummeted consequent to the flattish sales growth.

In FY03, the company finished with just over 12% topline growth, with a marginal operating margin decline (can be attributed to the poor March quarter margins). Cipla managed to grow its bottomline by a staid 5% during the year. This growth was possible only because of a 12% dip in tax provisions, which came about owing to the tax benefits of the new Goa plant.

Cost snapshot
(Rs m) 4QFY02 4QFY03 Change FY02 FY03 Change
(Increase)/decrease in stock in trade -444 -249 - -851 -787 -
Raw material cost 2,002 2,235 11.6% 6,908 7,968 15.4%
Staff cost 178 191 7.2% 633 729 15.2%
Other expenses 1,318 1,234 -6.4% 4,272 4,651 8.9%
Total expenditure 3,055 3,411 11.7% 10,961 12,561 14.6%

The stock tanked today and touched new 52-week lows of Rs 565. Currently, at Rs 634 the stock trades at 15.4x FY03 earnings. We believe that the long term prospects of the company are good and are encouraged by the continuing export growth. However, the slowdown in the domestic markets is a cause for concern and may temper sentiment in the short term.


Equitymaster requests your view! Post a comment on "Cipla: Domestic market blues...". Click here!

  

More Views on News

CIPLA Announces Quarterly Results (1QFY21); Net Profit Up 21.4% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, CIPLA has posted a net profit of Rs 6 bn (up 21.4% YoY). Sales on the other hand came in at Rs 43 bn (up 7.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (4QFY20); Net Profit Down 35.1% (Quarterly Result Update)

May 19, 2020 | Updated on May 19, 2020

For the quarter ended March 2020, CIPLA has posted a net profit of Rs 2 bn (down 35.1% YoY). Sales on the other hand came in at Rs 44 bn (down 0.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 9, 2019 | Updated on Sep 9, 2019

Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

More Views on News

Most Popular

How the 8-Year Cycle Can Help Identify Multibaggers (Fast Profits Daily)

Sep 11, 2020

This is how you can apply the greed and fear cycle in the market to pick stocks.

I Recommended this Stock over Page Industries because it's Relevant to Doubling Your Income (Profit Hunter)

Sep 7, 2020

Things are not often what they seem in the market and how you can take advantage of this.

The NASDAQ Whale Could Harm Your Portfolio (Fast Profits Daily)

Sep 7, 2020

The discovery of Softbank pushing up prices on the NASDAQ will cause volatility in the market. Stay alert!

This Could Be the Best September for Auto Stocks (Profit Hunter)

Sep 11, 2020

Here's why I think this month could be a great for auto stocks.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Sep 18, 2020 (Close)

TRACK CIPLA

CIPLA - TEVA PHARMA COMPARISON

COMPARE CIPLA WITH

MARKET STATS